Back

The Drug-Induced Respiratory Disease Website and App

CAR T-cell therapy

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.ao

Pulmonary infiltrates

II - Pulmonary edema - Acute lung injury - ARDS

II.a

Pulmonary edema, noncardiogenic (NCPE)
II.b

ARDS - Acute lung injury
II.q

Interstitial pulmonary edema
II.v

Acute respiratory or cardiopulmonary failure

III - Pulmonary/alveolar/airway hemorrhage/bleeding

III.c

Hemoptysis

V - Pleural and/or pericardial involvement

V.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI - Pulmonary vasculopathy

VI.a

Pulmonary embolism - Venous thrombosis/thromboembolism

X - Systemic/Distant conditions, syndromes and reactions

X.an

Cytokine release syndrome - Cytokine storm

XII - Cardiovascular involvement / toxicity

XII.a

Left or biventricular dysfunction/failure
XII.c

Pericardial effusion (w/wo tamponade)
XII.f

Cardiomyopathy (acute, subacute, chronic)
XII.l

Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
XII.m

Cardiac- cardiorespiratory/pulmonary arrest
XII.n

Cardiovascular collapse - Cardiogenic shock - Hypotension
XII.p

QTc prolongation
XII.r

Heart failure (biventricular, congestive)
XII.af

Coronary vasospasm - Vasospastic angina
XII.ah

Tachycardia
XII.ai

Cardiotoxicity
XII.ba

Sudden cardiac death
XII.bt

ST segment elevation
XII.cd

ST segment changes

XVII - Infections & related conditions

XVII.b

Opportunistic pulmonary/systemic infections